291 related articles for article (PubMed ID: 16052222)
1. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
Schmidt H; Bastholt L; Geertsen P; Christensen IJ; Larsen S; Gehl J; von der Maase H
Br J Cancer; 2005 Aug; 93(3):273-8. PubMed ID: 16052222
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract][Full Text] [Related]
5. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
Donskov F; von der Maase H
J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
7. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
9. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
Trivanović D; Petkovic M; Stimac D
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
[TBL] [Abstract][Full Text] [Related]
10. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
Teramukai S; Kitano T; Kishida Y; Kawahara M; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Furuse K; Fukushima M
Eur J Cancer; 2009 Jul; 45(11):1950-8. PubMed ID: 19231158
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
[TBL] [Abstract][Full Text] [Related]
13. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
16. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
17. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
[TBL] [Abstract][Full Text] [Related]
18. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
[TBL] [Abstract][Full Text] [Related]
19. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
